FDA Wants to Know How to Test Ibogaine Without Stopping Hearts, and It Is Asking You

Ibogaine can stop a heart. That is the sentence the FDA built its newest psychedelic notice around, and it is the one the internet leaves out when someone says ibogaine ended their cravings overnight.

Asking the public how to test ibogaine safely is the right first move, and anyone selling it as a shortcut before that answer exists is gambling with other people’s hearts.

In a notice published as Federal Register document 2026-20427, FDA asked for public comment on how early-phase trials of ibogaine for opioid use disorder and PTSD can be run safely. The worry has a name. Ibogaine can lengthen what doctors call the QTc interval, the pause a heart takes to electrically reset between beats, and a long enough pause can trigger a rhythm called Torsades de pointes that can kill. Lachman Consultants’ summary of the notice quotes FDA’s own warning that “risks, such as substantial QTc prolongation, can be a basis for not approving a drug.”

The agency is asking about the unglamorous parts that decide whether a trial protects people: how doses are chosen and raised, where treatment happens, how the heart is monitored, who is excluded, when a study must stop, and who watches over safety. The notice sits inside a faster policy lane. It cites the April 18, 2026 executive order 14401 on accelerating treatments for serious mental illness, and FDA’s July 14 guidance on psychedelic clinical investigations. FDA has also allowed an early-phase study of noribogaine, an ibogaine derivative, for alcohol use disorder, according to the same summary.

Know the gate before you read any of that as access. A request for comment is not an approval. Ibogaine is not a prescribable medicine anywhere in the United States, and no state pharmacy counter or clinic can offer it as treatment tomorrow. The notice, as Lachman describes it, does not state a comment deadline; check the Federal Register document for the date before you plan around it.

If you work in treatment, the move this week is small and concrete: ask your team who would screen patients asking about ibogaine for heart conditions and for the other QT-prolonging medications they take, because the question will arrive in your waiting room before the trial results do. If you are someone who has wondered whether this could be your way out, the medicines that already cut overdose death, buprenorphine and methadone, are available now, and no comment period stands between you and them.

Ibogaine may yet earn its place. The first test of whether anyone deserves your trust with it is whether they will tell you what it does to your heart.